Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case s...
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series
About this item
Full title
Author / Creator
Publisher
England: BMJ Publishing Group Ltd and British Society of Gastroenterology
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group Ltd and British Society of Gastroenterology
Subjects
More information
Scope and Contents
Contents
ObjectiveTreatment options for non-hospitalised patients with coronavirus disease 2019 (COVID-19) to reduce morbidity, mortality and spread of the disease are an urgent global need. The over-the-counter histamine-2 receptor antagonist famotidine is a putative therapy for COVID-19. We quantitively assessed longitudinal changes in patient reported ou...
Alternative Titles
Full title
Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7299656
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7299656
Other Identifiers
ISSN
0017-5749
E-ISSN
1468-3288
DOI
10.1136/gutjnl-2020-321852
